These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24466582)

  • 1. Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
    Liew A; Darvish-Kazem S; Douketis JD
    Pol Arch Med Wewn; 2013; 123(11):617-22. PubMed ID: 24466582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of new anticoagulants in primary practice.
    Perez A; Eraso LH; Merli GJ
    Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New direct oral anticoagulants and venous thromboprophylaxis].
    Degirmenci SE; Steib A
    Rev Prat; 2013 Sep; 63(7):976-9. PubMed ID: 24167901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Kovács T
    Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new generation of oral direct anticoagulants.
    Soff GA
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):569-74. PubMed ID: 22345595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulation in atrial fibrillation: a new era has begun].
    Moser M; Bode C
    Hamostaseologie; 2012; 32(1):37-9. PubMed ID: 22124808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
    Goldhaber SZ
    Thromb Haemost; 2012 Mar; 107(3):397-8. PubMed ID: 22318737
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stroke prevention in atrial fibrillation : old and new anticoagulants].
    Darius H; Sommer S
    Herz; 2013 May; 38(3):231-8. PubMed ID: 23632424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evidence of novel oral anticoagulants (NOAC)].
    Kitazono T
    Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
    Kornej J; Potpara T; Lip GY
    Pol Arch Med Wewn; 2013; 123(11):623-34. PubMed ID: 24104195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
    Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Moia M; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Siragusa S; Manotti C
    J Thromb Haemost; 2012 Oct; 10(10):1979-87. PubMed ID: 22827490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.